-

07:11:01 PM

GALT Stock News

GALT - Galectin Therapeutics Inc

03/16/23 8:00 AM

Nasdaq : GALT

clinical trial

Galectin Therapeutics Reports the Positive Outcome of the Third Data and Safety Monitoring Board Meeting for NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today reported the positive outcome of its third data and safety monitoring board (DSMB) meeting for NAVIGATE, its seamless, adaptive, phase

RHEA-AI

neutral

03/02/23 8:00 AM

Nasdaq : GALT

clinical trial

Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced that in late December 2022, it ended the enrollment of new patients into NAVIGATE, its seamless, adaptive, phase 2b/3 study of

RHEA-AI

neutral

01/24/23 8:00 AM

Nasdaq : GALT

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

Study to improve histology interpretation of cirrhotic liver biopsies highlights limitations of current histology techniques and re-emphasizes the clinical relevance and regulatory potential of esophago-gastric endoscopies when evaluating candidate therapies for liver cirrhosis. NORCROSS, Ga., Jan.

RHEA-AI

neutral

01/05/23 8:00 AM

Nasdaq : GALT

clinical trial

Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin in Patients with Liver Cirrhosis Caused by Non-Alcoholic Steatohepatitis

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, announced today that in late December 2022, it ended enrollment of NAVIGATE, its seamless, adaptive, phase 2b/3 study of belapectin in

RHEA-AI

neutral

11/29/22 8:00 AM

Nasdaq : GALT

conferences

Galectin Therapeutics to Webcast Corporate Update on December 1, 2022 after Annual Meeting of Stockholders

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, announced today that management will present a corporate update via live webcast immediately following the business portion of its 2022

RHEA-AI

neutral

11/28/22 8:00 AM

Nasdaq : GALT

conferences

Galectin Therapeutics to Present at 6th Obesity & NASH Drug Development Summit

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at the 6 th Obesity and NASH Drug Development Summit in Boston, MA. On November 30, 2022,

RHEA-AI

neutral

11/14/22 8:00 AM

Nasdaq : GALT

earnings

Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended September 30, 2022. These results are

RHEA-AI

neutral

11/01/22 8:00 AM

Nasdaq : GALT

Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2022, Hosted by the AASLD

Prevalence of esophageal and gastric varices in patients with compensated NASH cirrhosis and portal hypertension Biochemical and imaging profiles in 271 patients with compensated NASH cirrhosis and portal hypertension Hepatic Expression of Galectin-3, a Pro-fibrotic and Pro-inflammatory Marker

RHEA-AI

neutral

10/14/22 8:00 AM

Nasdaq : GALT

conferences

Galectin Therapeutics to Present in Upcoming Conferences

Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, announced today the Company will be presenting at two upcoming conferences. On October 17, 2022, management will present in the H.C.

RHEA-AI

neutral

10/12/22 8:00 AM

Nasdaq : GALT

fda approval

Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer

Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin-3, today announced that its Investigational New Drug (IND) application for belapectin in combination with a checkpoint inhibitor for the

RHEA-AI

very positive

1 2 3 4 5 6 Next

GALT Data

IndustryPharmaceutical Preparation Manufacturing
Websitewww.galectintherapeutics.com
CeoHarold Shlevin
Security nameGalectin Therapeutics Inc
Issue typecs
SectorManufacturing
Sic code2834
Employees6
Tags
- Health Technology
- Biotechnology
- Manufacturing
- Pharmaceutical Preparation Manufacturing
Address4960 Peachtree Industrial Blvd Ste 240
StateGeorgia
CityBerkeley Lake
Zip30071-1580
CountryUS
Phone16786203186

About Galectin Therapeutics Inc

Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin's lead drug belapectin (formerly known as GR-MD-02) is a carbohydrate-based drug that inhibits the galectin-3 protein which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in non-alcoholic steatohepatitis (NASH) with cirrhosis, the most advanced form of NASH-related fibrosis. This is the most common liver disease and one of the largest drug development opportunities available today. Additional development programs are in treatment of combination immunotherapy for advanced melanoma and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development.